Breadcrumb

Photo of Dr. Danielle Arnold with a white background

Danielle E. Arnold, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Assistant Research Physician
Immune Deficiency Cellular Therapy Program

RESEARCH SUMMARY

Dr. Arnold’s primary interest is to develop and optimize hematopoietic cell transplantation regimens for patients with primary immunodeficiencies and primary immune regulatory disorders. Her clinical focus at the NIH has been on patients with GATA2 deficiency, and she is developing a novel transplant regimen for GATA2 deficiency patients using an anti-c-kit antibody-based conditioning regimen. She is also investigating the role of autoinflammatory disease and transplant outcomes in patients with chronic granulomatous disease through her work with the Primary Immune Deficiency Treatment Consortium (PIDTC).

Areas of Expertise

Pediatric Hematopoietic Cell Transplantation
Primary Immune Deficiency And Immune Regulatory Disorders
GATA2 Deficiency
Hemophagocytic Lymphohistiocytosis
Chronic Granulomatous Disease

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Clinical Trials

  • Open - Recruiting
    Summary Not Yet Available. Call Referral Contact.

    A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation with JSP191-Based Conditioning in Participants with GATA2 Deficiency

    Protocol ID
    IRB001531

Publications

Selected Key Publications

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD

Arnold DE, Nofal R, Wakefield C, Kehmberg K, Wustrau K, Albert MH, Morris EC, Heimall JR, Bunin NJ, Kumar A, Jordan MB, Cole T, Choo S, Brettig T, Speckmann C, Ehl S, Salamonowicz-Bodzioch M, Walhstrom J, Rao K, Booth C, Worth A, and Marsh RA
Journal of Clinical Immunology. 1-10, 2021.
Full-Text Article
[ Journal Article ]

A prospective pilot study of a novel alemtuzumab target concentration intervention strategy

Arnold DE, Emoto C, Fukuda T, Vinks AA, Dong M, Vinks AA, Lane A, McIntosh K, Neumeier L, Lankester AC, Achini F, Teusink-Cross A, Chandra S, Jordan MB, Nelson AS, Myers KS, Davies SM, Mehta PA, and Marsh RA
Bone Marrow Transplantation. 56/12: 3029-3031, 2021.
Full-Text Article
[ Journal Article ]

Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients

Arnold DE, MacMath D, Seif AE, Heimall JR, Wang Y, Monos D, Grupp SA, and Bunin NJ.
Transplantation and Cellular Therapy . 27/2: 169.e1-169.e9, 2021.
Full-Text Article
[ Journal Article ]

Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT

Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Martinez C, Chellapandian D, Davila Saldana BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, and Kang EM.
Journal of Clinical Immunology. 39/7: 653-667, 2019.
Full-Text Article
[ Journal Article ]

Allogeneic hematopoietic stem cell transplantation in adolescent patients with chronic granulomatous disease

Arnold DE, Seif AE, Jyonouchi J, Sullivan KE, Bunin NJ and Heimall JR.
The Journal of Allergy and Clinical Immunology: In Practice. 7/3: 1052-1054.e2, 2019.
Full-Text Article
[ Journal Article ]